The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CERT | -39.24% | -73.23% | -23.15% | -81% |
| S&P | +17.45% | +75.43% | +11.88% | +84% |
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Princeton, NJ.
Certara provides biosimulation software and regulatory solutions to global biopharma clients, supporting drug development and approvals.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $103.65M | 3.3% |
| Gross Profit | $50.03M | 4.0% |
| Gross Margin | 48.26% | 0.3% |
| Market Cap | $1.40B | -18.2% |
| Market Cap / Employee | $890.35K | 0.0% |
| Employees | 1.6K | 1.9% |
| Net Income | -$5,895.00K | -189.6% |
| EBITDA | $24.37M | -5.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $189.39M | 5.7% |
| Accounts Receivable | $103.23M | 1.3% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $298.57M | -1.7% |
| Short Term Debt | $6.88M | -17.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -0.10% | 0.7% |
| Return On Invested Capital | -1.87% | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $27.81M | -43.2% |
| Operating Free Cash Flow | $28.82M | -41.6% |
| Metric | Q2 2025 | Q3 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 236.84 | 181.31 | - | ||
| Price to Book | 1.51 | 1.74 | 1.83 | 1.32 | -18.93% |
| Price to Sales | 4.05 | 4.64 | 4.72 | 3.35 | -24.87% |
| Price to Tangible Book Value | -8.68 | -12.15 | -11.48 | -8.37 | -42.21% |
| Price to Free Cash Flow TTM | 17.38 | 18.75 | 16.96 | 14.84 | -31.88% |
| Enterprise Value to EBITDA | 63.78 | 84.48 | 82.34 | 62.33 | -13.18% |
| Free Cash Flow Yield | 5.8% | 5.3% | 5.9% | 6.7% | 46.80% |
| Return on Equity | -0.2% | 0.8% | 1.0% | -0.2% | -86.86% |
| Total Debt | $309.17M | $307.86M | $306.68M | $305.45M | -2.07% |
No podcast episodes available.
CERT earnings call for the period ending June 30, 2022.
CERT earnings call for the period ending March 31, 2022.
CERT earnings call for the period ending December 31, 2021.
CERT earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
